HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gillette

This article was originally published in The Rose Sheet

Executive Summary

Second quarter results will be lower than expected, with sales increasing in the low single digits and earnings per share down 20%, the company announced June 17. Gillette's razors and blades business should make "good progress," driven by Mach 3 sales, which are "exceeding expectations," the company noted. While the toiletries, Braun and stationery businesses have "shown progressive improvement" since the first quarter, "sales have been softer than originally anticipated." In addition, certain overseas markets, including Brazil, Germany, Japan and Russia, have not recovered at the rate anticipated. Separately, the board approved an expansion of a share repurchase program from 50 mil. to 75 mil. shares. Fifty million shares will be bought back by the end of 1999, with the remaining repurchased within 12 to 18 months

Latest Headlines
See All
UsernamePublicRestriction

Register

RS006820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel